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nnuh.nhs.ukSummaryAddison’s disease is a condition characterised by immune-mediated destruction of the adrenal glands leading to a
requirement of lifelong replacement therapy with mineralocorticoid and glucocorticoid. We present a case of a 53-year-old
man who presented at the age of 37 years with nausea, fatigue and dizziness. He was found to have postural
hypotension and buccal pigmentation. His presenting cortisol level was 43 nmol/l with no response to Synacthen testing.
He made an excellent response to conventional replacement therapy with hydrocortisone and fludrocortisone and then
remained well for 16 years. On registering with a new endocrinologist, his hydrocortisone dose was revised downwards
and pre- and post-dose serum cortisol levels were assessed. His pre-dose cortisol was surprisingly elevated, and so his dose
was further reduced. Subsequent Synacthen testing was normal and has remained so for further 12 months. He is now
asymptomatic without glucocorticoid therapy, although he continues on fludrocortisone 50 mg daily. His adrenal antibodies
are positive, although his ACTH and renin levels remain elevated after treatment. Addison’s disease is generally deemed
to lead to irreversible cell-mediated immune destruction of the adrenal glands. For this reason, patients receive detailed
counselling and education on the need for lifelong replacement therapy. To our knowledge, this is the third reported case of
spontaneous recovery of the adrenal axis in Addison’s disease. Recovery may therefore be more common than previously
appreciated, which may have major implications for the treatment and monitoring of this condition, and for the education
given to patients at diagnosis.Learning points:
† Partial recovery from Addison’s disease is possible although uncommon.
† Patients with long-term endocrine conditions on replacement therapy still benefit from regular clinical and
biochemical assessment, to revisit optimal management.
† As further reports of adrenal axis recovery emerge, this may influence the counselling given to patients with
Addison’s disease in the future.Background
Addison’s disease is characterised by cell-mediated
immune destruction of the adrenal glands, either in
isolation or as part of a polyglandular autoimmune
syndrome. This process is widely deemed to be irreversible.
As such, patients with Addison’s disease require extensiveeducation on the importance of lifelong replacement
therapy with glucocorticoid and mineralocorticoid. We
present a new case of autoimmune Addison’s disease
where adrenal function appears to be restored over time.
This appears to be the second ever recorded case of
spontaneous recovery. It is uncertain whether this is trulyhttp://www.edmcasereports.com
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be more common with modern dosing regimens
if patients with Addison’s are regularly reassessed.0
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Figure 1
The x axis shows the serum cortisol response in nmol/l to standard short
Synacthen testing. The results (0 and 30 min only) at diagnosis in 1997 are
shown in the filled squares, the results in 2012 during treatment but 24 h
following any hydrocortisone dose are shown in the filled circles, and his
latest results in 2013 are shown in the filled triangles.Case presentation
A 37-year-old male soldier presented in 1997 with classical
Addison’s disease. He presented with fatigue, nausea,
vomiting, weight loss, malaise and dizziness. On exami-
nation, marked skin and buccal hyperpigmentation and
orthostatic hypotension were diagnosed. There was no
relevant family history. Baseline biochemistry was highly
suggestive of Addison’s disease: sodium 132, potassium
6.1, urea 8.5 mmol/l and random cortisol 43 nmol/l. There
was no response to 250 mg Synacthen test: cortisol level
rose to 56 nmol/l at 30 min. Adrenal antibodies and ACTH
and renin levels were not checked at that time.
He was treated conventionally with hydrocortisone
20 mg on waking, 10 mg midafternoon and fludrocorti-
sone 50 mg daily, resulting in an excellent recovery.
He then remained well for the next 12 years, but on
registering with a new endocrinologist, his hydrocortisone
requirement was reassessed. Gradual dose reduction was
suggested, and pre- and post-dose serum cortisol levels
were also checked. His pre-dose cortisol was surprisingly
elevated at 359 nmol/l, rising to 1181 nmol/l 2 h post-
hydrocortisone dose. His hydrocortisone dose was there-
fore reduced to 20 mg on waking and 5 mg midafternoon
due to patient’s reluctance to reduce his morning dose
further. Repeat Synacthen testing was then performed and
confirmed to be normal (Fig. 1). Hydrocortisone dose
was therefore cautiously and slowly reduced further. He
noticed no change in his symptoms and continued to
walk 6 miles to work daily, with an ongoing normal blood
pressure and serum electrolytes on 5 mg hydrocortisone
on waking only. On repetition of Synacthen testing, a rise
in cortisol level from 335 to 596 nmol/l was observed.
Hydrocortisone dose was therefore completely withdrawn
and the patient remains well after 4 months of treatment.
After treatment, his 0900 h ACTH level was initially
elevated at 86 ng/l but has now normalised at 13 ng/l.
Renin remains elevated 24 h post-fludrocortisone dose,
and so this has been continued. Adrenal antibody tests
are positive.Investigation
The 1997 initial Synacthen test results: peak cortisol
56 nmol/l at 30 min. 03/2012 Pre-dose cortisol
359 nmol/l, rising to 1181 nmol/l 2 h post-hydrocortisonehttp://www.edmcasereports.comdose (Z15 years after starting treatment for confirmed
Addison’s disease). 09/2012 Synacthen test results, taken
24 h after last dose of 20 mg hydrocortisone: baseline
cortisol 538 nmol/l, 30-min cortisol 555 nmol/l and
60-min cortisol 579 nmol/l. 09/2012 ACTH 86 ng/l,
renin 158 mU/l 24 h after any glucocorticoid or miner-
alocorticoid doses. 05/2013 Synacthen test: baseline
cortisol 335 nmol/l, 30-min cortisol 533 nmol/l and
60-min cortisol 596 nmol/l. ACTH 13 ng/l and renin
203 mU/l.
Autoimmune screening was not performed at
diagnosis. In 2013 thyroid peroxidase and tissue trans-
glutaminase antibodies are negative. Anti-smooth muscle
antibodies are also positive at a dilution of 1/320 but the
rest of his autoantibody screening including anti-nuclear
antibodies are negative. Adrenal antibodies are positive
as tested using a semi-automated immunofluorescence
method (using pre-coated monkey adrenal slides
and a commercially available conjugate, both from
INOVA Diagnostics San Diego, California, US).
Unfortunately, they had never been tested previously.Treatment
Hydrocortisone was cautiously withdrawn completely in
June 2013 following several months on very low-dose
therapy with no adverse effects and a persistently normal
Synacthen test. The patient also remains on fludrocorti-
sone 50 mg on waking in view of the persistently elevated
renin when this has been omitted for testing.2
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Hydrocortisone was stopped completely in June 2013,
16 years after the initial diagnosis of Addison’s disease was
made. The patient remains asymptomatic and well. The
patient also has an emergency supply of hydrocortisone
for both oral and i.m. administration in the event of
intercurrent illness. He and his family have also received
extensive education from a specialist endocrine nurse to
ensure that they understand the unusual nature of his
situation. He will be followed closely for the development
of other autoimmune endocrine conditions, and with
regular monitoring of his early morning cortisol levels
with repeat Synacthen testing when indicated to detect
any deterioration in his adrenal function in future.
We also plan to check his aldosterone level and to
consider stopping his fludrocortisone dose if this is
detectable, and the patient remains well, although
unfortunately, this has not been previously assessed.Discussion
This represents the third and most clear-cut documented
case of a patient with confirmed Addison’s disease with
spontaneous recovery. Smans et al. (1) documented a
patient who was able to stop treatment after 7 years, but
with ongoing subnormal response to Synacthen testing.
More recently, a second case was described with bio-
chemical Addison’s disease (peak cortisol 175 nmol/l)
presenting in pregnancy and complicated by concurrent
use of inhaled steroids and enzyme-inducing drugs (2).
This patient had fluctuating responses to Synacthen on
follow-up and has required intermittent glucocorticoid
replacement therapy. We describe the first case with
unequivocally abnormal biochemistry at diagnosis (peak
cortisol 56 nmol/l) and unequivocably normal biochem-
istry after 16 years of treatment (peak cortisol 579 nmol/l).
This raises several interesting issues. The first is that
endocrinologists need to be more vigilant at continually
reassessing patients with established or presumed diag-
noses, particularly if these have been made elsewhere. In
this case, a patient with a very well-defined and confirmed
biochemical diagnosis of Addison’s was reassessed due
to his somewhat old-fashioned and supraphysiological
glucocorticoid replacement regimen. This led to more
detailed biochemical assessment than had previously
been undertaken and revealed that he no longer required
daily glucocorticoid replacement therapy at all. It is now
impossible to determine how many years of potentially
unnecessary glucocorticoid therapy this patient hadhttp://www.edmcasereports.combeen exposed to if any. It is reassuring that there were
no clinical signs of supraphysiological glucocorticoid
treatment in this case, although obvious side effects may
have led the diagnosis to be challenged earlier.
A recent study performed short Synacthen tests on
27 patients with established Addison’s disease. The authors
did not uncover any other examples of spontaneous
recovery (3). It is possible that this cohort was very
small and that the phenomenon is still more common
than previously thought. It is also unknown whether any
specific characteristics might predict which patients could
recover over time. The patient described here continues
to have positive adrenal antibodies, which might be taken
as a negative predictor of recovery. On the other hand,
he has no family history, no other autoimmune con-
ditions and ongoing normal thyroid function that might
be a more positive sign.
Furthermore, it is possible, that a subset of patients
with Addison’s disease and the potential for adrenal
recovery might only exhibit this recovery when their
glucocorticoid dose is reduced into more physiological
ranges. Recovery was only detected after the dose of
glucocorticoid was slowly reduced in the first reported
case (1). In another case, subclinical hypoadrenalism in
association with Graves’ disease was reported to improve
after treatment of the patient with high-dose steroids
for their ophthalmopathy (4). In this case, the patient
had been taking 30–40 mg hydrocortisone for many
years but was not exposed to any other or higher dose
immunosuppressives that might have ‘treated’ an
immune adrenalitis and so contributed to his subsequent
recovery. It is possible that the reduction in his total
daily dose allowed his recovery, by releasing his
hypothalamo-pituitary–adrenal axis from supraphysio-
logical suppression, but the dose used, length of time
since diagnosis, the early increase in ACTH on treatment
withdrawal and the continued presence of positive adrenal
antibodies go against this mechanism.
Other studies have explored patients with positive
adrenal antibodies but without overt Addison’s disease (5).
Anti-adrenal antibodies are associated with Addison’s
disease, but in this study of 20 patients with positive
antibodies, some showed spontaneous disappearance
of the antibodies, and no subsequent Addison’s, some
showed a progression through subclinical hypoadrenalism
and then overt Addison’s disease with persistently positive
antibodies, while others developed clear Addison’s disease
but with subsequent loss of their antibodies. No episodes
of recovery were detected. This seems to offer the most
plausible mechanism to explain these cases: perhaps3
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fluctuate in character and quantity leading to unpredict-
able adrenal function over time.
Finally, it is possible that his initial confirmed
glucocorticoid deficiency was non-immune in nature.
The pigmentation at presentation, suggesting elevated
ACTH, goes against the possibility of adrenal suppression
from exogenous steroid exposure. Similarly, malignancy,
tuberculosis, adrenal haemorrhage or infarction would be
expected to be clinically obvious either at presentation or
over such a long follow-up period, and the presence of
adrenal and other autoantibodies now does support the
supposition that this was immune-mediated Addison’s
disease. However, this cannot be confirmed 100%.
In summary, recovery from Addison’s disease is
possible, although we do not yet know whether this will
be sustained long term in this case. Similarly, we have no
current models to predict which patients are more likely to
recover than others. Vigilance in the follow-up of patients
with long-term endocrine conditions is therefore para-
mount. Secondly, all opportunities to revise glucocorti-
coid dosing downwards where possible should be sought.
Finally, this case demonstrates the importance of patient
involvement in the management of long-term conditions
and has absolutely relied on detailed educational input
from a specialist nurse to maintain his safety.Declaration of interest
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